A peptide exhibiting diabetogenic and anti-insulin properties isolated from bovine adenohypophysis was administered subcutaneously in single doses to four dogs for 2 to 3 consecutive days. Ten hours after each injection, the animals were given an oral glucose load and a series of blood samples were obtained for glucose and insulin determinations. In one dog, the procedure was repeated 13 days after the first one. In another animai, the same procedure was carried out three times. Glucose tolerance was clearly impaired and serum in&in rose excessively in three of the four animals. In the fourth animal the response was observed but only after the third injection. Thus, insulin resistance appears to be a major mechanism by which this peptide induces loss of carbohydrate tolerance. The substance is not present in the urine of proteinuric patients without diabetes, diabetics without proteinuria and healthy people.2 A similar diabetogenic peptide has also been isolated from the adenohypophyses of beef,3 hog and sheep.4 The peptide from all of these sources produces hyperglycemia and induces antagonism to the action of exogenous insulin when administered to dogs or man. The mechanism by which the peptide acts has not been known but it was inferred from the above mentioned findings that resistance to endogenous insulin was probably a major factor.
mai, the same procedure was carried out three times. Glucose tolerance was clearly impaired and serum in&in rose excessively in three of the four animals. In the fourth animal the response was observed but only after the third injection. Thus, insulin resistance appears to be a major mechanism by which this peptide induces loss of carbohydrate tolerance. (Metabolism 20: No. 3, March, 326-330, 1971) P REVIOUS PUBLICATIONS from this laboratory have demonstrated the presence of a diabetogenic peptide in the urine of patients with lipoatrophic diabetes1 and of proteinuric diabetic patients without lipoatrophy.2 The substance is not present in the urine of proteinuric patients without diabetes, diabetics without proteinuria and healthy people.2 A similar diabetogenic peptide has also been isolated from the adenohypophyses of beef,3 hog and sheep. 4 The peptide from all of these sources produces hyperglycemia and induces antagonism to the action of exogenous insulin when administered to dogs or man. The mechanism by which the peptide acts has not been known but it was inferred from the above mentioned findings that resistance to endogenous insulin was probably a major factor.
In an attempt to study this possibility we have administered subcutaneously in dogs the peptide obtained from bovine adenohypophysis and have measured the serum insulin and blood glucose responses to glucose administered by gastric tube. The results indicate that resistance to endogenous insulin is a major factor in the mechanism by which the peptide induces hyperglycemia.
MATERIALS AND METHODS
Isolation of a diabetogenic peptide, designated as PI, from bovine adenohypophysis has been described. 3 The isolated substance is prepared for injection by solution in dilute hydrochloric acid (0.05-0.1 N) and neutralization with 0.05 N NaOH to pH 7.0-7.4. The solution has been administered subcutaneously as a single dose.
Four trained dogs, one female and three males, were studied. They were maintained between tests on a diet of Friskies Mix dog food and one can of Pard. For 3 days prior to and throughout the testing periods, the daily diet consisted of 454 Gm. of Pard, 100 Gm. Friskies and 60 Gm. of sucrose. No food was eaten after 10:00 p.m. Oral (gastric intubation) glucose tolerance tests were begun between 8:00 and 9:00 a.m. The experimental procedure consisted of two control glucose tolerance tests done on days 1 and 2; a subcutaneous injection of the peptide 10 hours before the third glucose tolerance test which was done on day 3; administration of a single dose of the peptide daily for two more days with glucose tolerance tests being done on days 4 and 5; and a final glucose tolerance test carried out 34 hours after the last injection of peptide (day 6). This series of tests is designated as "Test Period I." Postpeptide glucose tolerance tests were carried out 13 and 14 days after the last administration of peptide. Following an interval of at least 13 days, a second similar testing period, "Test Period II," was begun. In one dog, "Test Period III" was also performed. 
RESULTS
Blood glucose and serum insulin values for Dog K are presented in Table 1 . Both insulin and glucose levels are greatly elevated by injection of this compound. Thirteen and fourteen days after peptide administration, the values had returned to normal. Dog 0, Table 2 , showed no significant change until the third day of peptide injection. There then occurred a mild rise of serum insulin and a marked impairment of glucose tolerance. The results of Dog T are depicted in Tables 3 and 4 . It is apparent that glucose tolerance was greatly impaired and that serum insulin levels rose sharply.
In both test periods, there occurred an important rise of the fasting serum insulin level as well. By 13 and 14 days after the last injection of peptide, blood glucose and insulin levels had returned to normal. The results on Dog L are shown in Tables 5 and 6 . The responses of this animal are very similar to those of Dog T, except that they are more intense. Again, the fasting serum insulin value was greatly elevated. However, in "Test Period III," glucose tolerance was normal and serum insulin was only mildly elevated. The reason for this finding is unclear at present. Perhaps a sufficient antibody titer had been produced to overcome the activity of the administered material. Studies in this area are in Table 5  Table 6 progress. It should be noted that for Dogs T and L, the doses of peptide administered were somewhat larger than those given to Dogs K and 0.
COMMENT
The present study demonstrates that administration of our bovine diabetogenic peptide to dogs results in hyperinsulinemia together with impairment of glucose tolerance. It has been shown that bovine growth hormone is also capable of inducing simultaneously hyperinsulinemia and hyperglycemia in dogs.S-g Because growth hormone and our peptide have similar diabetogenic properties, we have compared the growth promoting activity of these two peptides by means of the tibia test of Greenspan et al. 10 It was found that our diabetogenic peptide has no significant growth promoting activity. 11 It has been shown that bovine growth hormone can be degraded by trypsin or chymotrypsin after which it may be capable of inducing carbohydrate intolerance in man.12*13 The possibility that our diabetogenic polypeptide is a part of the growth hormone molecule cannot be excluded completely but it is an unlikely one, since no diabetogenic peptide at pH 4.1 was obtained when bovine growth hormone (NIH-GH-B8) itself was subjected to our procedure of isolation. Previous results from this laboratory have shown that our substance has no ACTH effects in man.3 No significant prolactin activity as measured by the Reece-Turner intradermal pigeon crop technique could be demonstrated. -I Thus, it seems reasonable to conclude that our substance is different from other known pituitary hormones.
The possibility exists that this substance may induce beta cell release of abnormal quantities of an immunodetectable moeity of insulin with low biological activity, such as proinsulin. We have not yet made these measurements but such a mechanism could not explain the entire phenomenon, since we have already found1-4 decreased sensitivity to intravenously administered exogenous insulin in dogs and men treated with this compound.
It is premature to speculate upon the possible physiological significance of this substance but it is important that we have recently isolated it from pituitary glands of rnan.lj
